James Allison and Robert Schreiber won the Balzan Prize for their contributions to immunological approaches in cancer therapy. According to the prize committee, “Professors Schreiber and Allison have played transformative roles in the field of tumor immunology, Schreiber by demonstrating that the immune system is crucially involved in fighting tumours and by introducing the concept...
On Aug. 26, FDA approved the RAS inhibitor, daraxonrasib, sponsored by Revolution Medicines Inc. and also known as Rasonque, for patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.
